Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Hagens Berman Sobol Shapiro LLPCAPR 10-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 DeadlineHagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with a premier securities practice group-notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application...
- OracleSan Juan Regional Medical Center Teams with Oracle Health to Streamline Patient FlowCompanies: Oracle CorporationSan Juan Regional Medical Center has strengthened its clinical operations with several new Oracle Health solutions that help streamline patient flow, ...
- Monteverde & Associates PCSHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The...
- OracleSan Juan Regional Medical Center Teams with Oracle Health to Streamline Patient FlowCompanies: Oracle CorporationClinicians and staff gain an up-to-date view of capacity, patient movement, and environmental services workflows — San Juan Regional Medical Center has strengthened its clinical operations with several new Oracle Health solutions that help...
- Eli Lilly and CompanyU.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancerCompanies: Eli Lilly and CompanyInluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3 EMBER-3 trial, Inluriyo in combination with Verzenio doubled median progression-free...
- Shockwave Centers of America Highlights Co-Founder Clinical Experience in Shockwave TherapyMARIETTA, GA - September 18, 2026 -
- "Why are we excluded?" CUPE personal support workers to rally to be treated like every other profession in OntarioTORONTO, September 18, 2026--Personal support workers have been often treated as lesser workers in the health care system – often by management, and certainly by the government.
- Southern California University of Health SciencesSouthern California University of Health Sciences Earns 2026 Great Colleges to Work For Honor Roll Distinction for Fourth Consecutive YearEmployee-driven recognition highlights SCU for job satisfaction, compensation and benefits, professional development, supervisor effectiveness, and confidence in senior leadership — Southern California University of Health Sciences (SCU) has...
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot UlcersLakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...
- Form 8.3 - Advanced Medical Solutions Group plc - Octopus InvestmentsFORM 8.3
- VulcanForms Inc.VulcanForms Appoints Jeff Hemenway Chief Revenue Officer to Accelerate GrowthManufacturing and growth veteran joins VulcanForms to lead global go-to-market operations as the company scales its digital-first manufacturing platform for commercial, medical, aerospace, defense and industrial customers BOSTON, Sept. 18, 2026 -- VulcanForms, an MIT-born,...
- XORTX Therapeutics Inc.XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market OpportunityInvestigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026